Pythium Vaccine for the Treatment of Non-Resectable Cutaneous Mast Cell Tumors in Dogs

Why are we doing this study?

Canine mast cell tumors are one of the most common skin cancers in dogs. Surgery is usually the treatment of choice when possible. If these tumors are unable to be removed (non-resectable) additional treatments such as chemotherapy or radiation therapy may be used. Additional treatment options are being investigated for the treatment of these tumors when surgery is not feasible. The use of an immune stimulating vaccine is being investigated for the effectiveness in canine cutaneous mast cell tumors. Pythium insidiosum is an infectious agent universal in distribution and is common in and near bodies of water. When Pythium extract is used for specific immunotherapy, an increase in the white blood cells responsible for identifying cancer cells is observed. In an early case series of canine patients with mast cell tumors, a 50% reduction in tumor size was seen. Side effects have not been observed from the vaccine, which is given under the skin once weekly.

How does my pet qualify?

If your dog has been diagnosed with a non-resectable cutaneous mast cell tumor, they may qualify. Your pet cannot be undergoing treatment with chemotherapy, radiation therapy or other immunotherapy at the same time as the clinical study. Treatment with prednisone is fine during the trial.

What are the benefits?

The cost of the vaccine is significantly reduced for use in patients enrolled in this clinical study. The costs of additional treatment for your pet’s mast cell tumor is not included as part of this study.

Who should I contact?

Please contact our staff for more information.